Literature DB >> 11858780

Endocrine Heart Disease.

Deepak R. Talreja1, Gregory W. Barsness.   

Abstract

With the increasing prevalence of obesity and diabetes mellitus in the United States, associated cardiovascular disease is reaching epidemic proportions with staggering economic and societal impact. Numerous studies have demonstrated the poorer prognosis associated with chronic coronary artery disease and acute coronary syndromes in patients with diabetes compared with nondiabetic patients. Although the therapeutic strategy is largely the same for the two populations, proper management of the diabetic patient with cardiovascular disease must account for the associated metabolic disturbances. Thyroid disease is the next most common endocrine disorder that affects proper function of cardiovascular patients; all patients presenting with coronary artery disease or cardiac arrhythmias should undergo screening with a sensitive thyroid-stimulating hormone assay and appropriate treatment when necessary. Though these areas are the most common points of intersection between the cardiologist and endocrinologist, a thorough understanding of the impacts of each endocrine system on cardiac function is essential to recognize disease entities that often present with a cardiovascular manifestation or affect patients with a primary cardiovascular disease.

Entities:  

Year:  2002        PMID: 11858780     DOI: 10.1007/s11936-002-0038-9

Source DB:  PubMed          Journal:  Curr Treat Options Cardiovasc Med        ISSN: 1092-8464


  35 in total

1.  Hormone replacement therapy and cardiovascular disease: a statement for healthcare professionals from the American Heart Association.

Authors:  L Mosca; P Collins; D M Herrington; M E Mendelsohn; R C Pasternak; R M Robertson; K Schenck-Gustafsson; S C Smith ; K A Taubert; N K Wenger
Journal:  Circulation       Date:  2001-07-24       Impact factor: 29.690

2.  Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients.

Authors:  S Yusuf; P Sleight; J Pogue; J Bosch; R Davies; G Dagenais
Journal:  N Engl J Med       Date:  2000-01-20       Impact factor: 91.245

Review 3.  Cardiovascular complications of malignant carcinoid disease.

Authors:  A S Anderson; D Krauss; R Lang
Journal:  Am Heart J       Date:  1997-10       Impact factor: 4.749

Review 4.  Management of hypertension in patients with type 2 diabetes mellitus: guidelines based on current evidence.

Authors:  N M Kaplan
Journal:  Ann Intern Med       Date:  2001-12-18       Impact factor: 25.391

5.  Cardiovascular morbidity and mortality associated with the metabolic syndrome.

Authors:  B Isomaa; P Almgren; T Tuomi; B Forsén; K Lahti; M Nissén; M R Taskinen; L Groop
Journal:  Diabetes Care       Date:  2001-04       Impact factor: 19.112

6.  Estrogen in the prevention of atherosclerosis. A randomized, double-blind, placebo-controlled trial.

Authors:  H N Hodis; W J Mack; R A Lobo; D Shoupe; A Sevanian; P R Mahrer; R H Selzer; C R Liu Cr; C H Liu Ch; S P Azen
Journal:  Ann Intern Med       Date:  2001-12-04       Impact factor: 25.391

7.  Glycometabolic state at admission: important risk marker of mortality in conventionally treated patients with diabetes mellitus and acute myocardial infarction: long-term results from the Diabetes and Insulin-Glucose Infusion in Acute Myocardial Infarction (DIGAMI) study.

Authors:  K Malmberg; A Norhammar; H Wedel; L Rydén
Journal:  Circulation       Date:  1999-05-25       Impact factor: 29.690

8.  Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. Heart and Estrogen/progestin Replacement Study (HERS) Research Group.

Authors:  S Hulley; D Grady; T Bush; C Furberg; D Herrington; B Riggs; E Vittinghoff
Journal:  JAMA       Date:  1998-08-19       Impact factor: 56.272

Review 9.  Pheochromocytoma. Update on diagnosis, localization, and management.

Authors:  S S Werbel; K P Ober
Journal:  Med Clin North Am       Date:  1995-01       Impact factor: 5.456

10.  Relation of endocrine and cardiac findings in acromegalics.

Authors:  G Kahaly; C Stover; J Beyer; S Mohr-Kahaly
Journal:  J Endocrinol Invest       Date:  1992-01       Impact factor: 4.256

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.